



STANDARD TREATMENTS AND NEW DIRECTIONS IN GYNAECOLOGICAL CANCERS

MILANO June 26th-29th, 2025

Responsabili Scientifici:
NICOLETTA COLOMBO, FRANCESCO RASPAGLIESI



OVARIAN CANCER TRIALS

Opening studies at relapse

Gemma Rossi, Ospedale Careggi, Firenze

Nessuna disclosure

OVARIAN CANCER TRIALS - relapse

Opening and planned

- ENGOT-ov84 / MK-2870-022 (platinum sensitive)
- LATER-OC (platinum sensitive)
- ENGOT-ov86 / RAINFOL-OV2 (platinum resistant)
- ENGOT-ov93 / TREVI (platinum resistant)

CONFIDENTIAL

LATER-OC

PLATinum-based second line chemotherapy after PARP-inhibitors in patients with ovarian cancer. Retrospective analysis of post-progression treatments

Sponsor	Istituto Europeo di Oncologia (IEO)
Coordination and Statistical analysis	Istituto di Ricerche Farmacologiche Mario Negri
Number of participating sites in Italy	20
Samples size	Approximately 200 patients

Ovarian cancer trials relapse – Opening **LATER-OC**

STUDY DESIGN: Non-interventional, retrospective, multicentre study aiming at evaluating the efficacy of second line platinum-based chemotherapy (PBC) in patients with recurrent High grade ovarian cancer previously treated with PARPi

RATIONALE: For patients with a platinum free interval (PFI) of at least 6 months, progressing both during and after maintenance therapy with PARPi, second line treatment with PBC is indicated. However, sensitivity and resistance to PBC and PARPi treatment partially overlaps: responses to PBC after ≥ 2 lines maintenance therapy with PARPi are dismal (7.0 months), as opposed for patients naive to PARPi (14.3 months)

PRIMARY ENDPOINT: progression free survival (PFS)

SECONDARY ENDPOINTS:

- Objective response rate (ORR) per RECIST 1.1
- Disease control rate (DCR) per RECIST 1.1
- Overall survival (OS)

STUDY TIMELINE:

Approval from EC: July 2024

First site activation (IEO): March 2025

Ovarian cancer trials relapse – Opening **LATER-OC**

LATER-OC: MaNGO SITES

#	Site	City	PI	status
1.	Istituto Europeo di Oncologia	Milano	Nicoletta Colombo	Active March 2025
2.	Ospedali Galliera	Genova	Nicoletta Provinciali	
3.	Policlinico S. Orsola	Bologna	Daniela Rubino	
4.	Ospedale Careggi	Firenze	Gemma Rossi	
5.	Ospedale Manzoni	Lecco	Antonio Ardizzoia	
6.	Ospedale di Mirano	Mirano	Alessandra Baldoni	
7.	Istituto Nazionale dei Tumori	Milano	Mara Mantiero	
8.	Istituto Oncologico Veneto	Padova	Giulia Tasca	
9.	Arcispedale S. Maria Nuova	Reggio Emilia	Alessandra Bologna	
10.	Policlinico Umberto I	Roma	Federica Tomao	
11.	Ospedale Infermi	Ponderano	Laura Zavallone	
12.	Ospedale San Luca	Lucca	Editta Baldini	
13.	Policlinico San Matteo	Pavia	Chiara Cassani	
14.	AOU Città della Salute e della Scienza Ospedale Mauriziano	Torino	Annamaria Ferrero	
15.	AOU di Modena	Modena	Roberto Sabbatini	
16.	AOU di Parma	Parma	Angelica Sikokis	
17.	Ospedale del Ponte	Varese	Nicoletta Donadello	
18.	Ospedale Santa Chiara	Pisa	Carmelo Bengala	
19.	ASST Spedali Civili	Brescia	Germana Tognon	
20.	AOU Città della Salute e della Scienza PO S.Anna	Torino	Piovano Elisa	

CONFIDENTIAL

Ovarian cancer trials relapse – Opening & planned **ENGOT-ov93 / TREVI**

CONFIDENTIAL

- ENGOT Model: C
- SPONSOR: AstraZeneca
- LEAD GROUP: **MaNGO**
- ENGOT Lead PI: Prof. Nicoletta Colombo